These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 25185193)

  • 41. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
    Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
    Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
    [No Abstract]   [Full Text] [Related]  

  • 42. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
    Soncini C; Carpinelli P; Gianellini L; Fancelli D; Vianello P; Rusconi L; Storici P; Zugnoni P; Pesenti E; Croci V; Ceruti R; Giorgini ML; Cappella P; Ballinari D; Sola F; Varasi M; Bravo R; Moll J
    Clin Cancer Res; 2006 Jul; 12(13):4080-9. PubMed ID: 16818708
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
    Zou HY; Li Q; Lee JH; Arango ME; McDonnell SR; Yamazaki S; Koudriakova TB; Alton G; Cui JJ; Kung PP; Nambu MD; Los G; Bender SL; Mroczkowski B; Christensen JG
    Cancer Res; 2007 May; 67(9):4408-17. PubMed ID: 17483355
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
    Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
    Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
    Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
    Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3D culture adds an extra dimension to targeted epigenetic therapies.
    Ozes AR; Nephew KP
    Cell Cycle; 2013 Jul; 12(14):2173-4. PubMed ID: 23803725
    [No Abstract]   [Full Text] [Related]  

  • 49. Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.
    Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10810-E10811. PubMed ID: 30377273
    [No Abstract]   [Full Text] [Related]  

  • 50. Functional relationship among PLK2, PLK4 and ROCK2 to induce centrosome amplification.
    Ling H; Hanashiro K; Luong TH; Benavides L; Fukasawa K
    Cell Cycle; 2015; 14(4):544-53. PubMed ID: 25590559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autoinhibition and relief mechanism for Polo-like kinase 4.
    Klebba JE; Buster DW; McLamarrah TA; Rusan NM; Rogers GC
    Proc Natl Acad Sci U S A; 2015 Feb; 112(7):E657-66. PubMed ID: 25646492
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Centriole duplication: when PLK4 meets Ana2/STIL.
    Kim M; Fong CS; Tsou MF
    Curr Biol; 2014 Nov; 24(21):R1046-8. PubMed ID: 25517369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies.
    Ward A; Sivakumar G; Kanjeekal S; Hamm C; Labute BC; Shum D; Hudson JW
    Leuk Lymphoma; 2015 Jul; 56(7):2123-33. PubMed ID: 25347426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct interaction of Plk4 with STIL ensures formation of a single procentriole per parental centriole.
    Ohta M; Ashikawa T; Nozaki Y; Kozuka-Hata H; Goto H; Inagaki M; Oyama M; Kitagawa D
    Nat Commun; 2014 Oct; 5():5267. PubMed ID: 25342035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plk4 phosphorylates Ana2 to trigger Sas6 recruitment and procentriole formation.
    Dzhindzhev NS; Tzolovsky G; Lipinszki Z; Schneider S; Lattao R; Fu J; Debski J; Dadlez M; Glover DM
    Curr Biol; 2014 Nov; 24(21):2526-32. PubMed ID: 25264260
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Centriole maturation requires regulated Plk1 activity during two consecutive cell cycles.
    Kong D; Farmer V; Shukla A; James J; Gruskin R; Kiriyama S; Loncarek J
    J Cell Biol; 2014 Sep; 206(7):855-65. PubMed ID: 25246616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role for polo-like kinase 4 in mediation of cytokinesis.
    Press MF; Xie B; Davenport S; Zhou Y; Guzman R; Nolan GP; O'Brien N; Palazzolo M; Mak TW; Brugge JS; Slamon DJ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(23):11309-11318. PubMed ID: 31097597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer.
    Suri A; Bailey AW; Tavares MT; Gunosewoyo H; Dyer CP; Grupenmacher AT; Piper DR; Horton RA; Tomita T; Kozikowski AP; Roy SM; Sredni ST
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.
    Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E
    Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1913-1918. PubMed ID: 29434041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment.
    Liu X
    Transl Oncol; 2015 Jun; 8(3):185-95. PubMed ID: 26055176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.